{"filing":{"accession_number":"0001193125-26-294445","cik":"0000884624","ticker":"OFIX","company_name":"Orthofix Medical Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"ofix-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526294445/ofix-20260701.htm"},"events":[{"id":15791,"run_id":14085,"accession_number":"0001193125-26-294445","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure reports a material regulatory and reimbursement development: the FDA reclassified non-invasive bone growth stimulators from Class III to Class II, CMS initially modified Medicare billing and fee schedules, but then withdrew those changes on July 1, 2026, restoring prior reimbursement rates. This is a significant operational and financial event affecting the Company's Medicare revenue for HCPCS codes E0747, E0748, and E0760, but it does not fit neatly into the specific financial or legal categories—it is a regulatory milestone with direct business impact that is best classified as an operational event.","company_name":"Orthofix Medical Inc.","ticker":"OFIX","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13687,"accession_number":"0001193125-26-294445","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports a material regulatory and reimbursement development: the FDA reclassified non-invasive bone growth stimulators from Class III to Class II, CMS initially modified Medicare billing and fee schedules, but then withdrew those changes on July 1, 2026, restoring prior reimbursement rates. This is a significant operational and financial event affecting the Company's Medicare revenue for HCPCS codes E0747, E0748, and E0760, but it does not fit neatly into the specific financial or legal categories—it is a regulatory milestone with direct business impact that is best classified as an operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:01:39.810462+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13687,"accession_number":"0001193125-26-294445","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports a material regulatory and reimbursement development: the FDA reclassified non-invasive bone growth stimulators from Class III to Class II, CMS initially modified Medicare billing and fee schedules, but then withdrew those changes on July 1, 2026, restoring prior reimbursement rates. This is a significant operational and financial event affecting the Company's Medicare revenue for HCPCS codes E0747, E0748, and E0760, but it does not fit neatly into the specific financial or legal categories—it is a regulatory milestone with direct business impact that is best classified as an operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:01:39.810462+00:00","company_name":"Orthofix Medical Inc.","ticker":"OFIX","filing_date":"2026-07-02"}]}